vTv Therapeutics (VTVT) Liabilities and Shareholders Equity (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $98.8 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 208.53% year-over-year to $98.8 million; the trailing twelve-month figure through Mar 2026 stood at $314.7 million (up 96.76% YoY), and the FY2025 full-year result was $89.9 million, up 134.93% from the prior year.
• Liabilities and Shareholders Equity grew to $98.8 million in Q1 2026, from $89.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $99.5 million in Q3 2025 to a low of $11.0 million in Q4 2023.
• A 5-year average of $43.1 million and a median of $35.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity sank 66.85% in 2023 and surged 247.3% in 2024, its largest moves.
• Tracing VTVT's Liabilities and Shareholders Equity over 5 years: stood at $33.2 million in 2022, then slumped by 66.85% to $11.0 million in 2023, then surged by 247.3% to $38.3 million in 2024, then soared by 134.93% to $89.9 million in 2025, then rose by 9.92% to $98.8 million in 2026.
• Business Quant data shows VTVT's Liabilities and Shareholders Equity at $98.8 million in Q1 2026, $89.9 million in Q4 2025, and $99.5 million in Q3 2025.